| Identification | Back Directory | [Name]
Faldaprevir | [CAS]
801283-95-4 | [Synonyms]
BI 201335
Faldaprevir
Faldaprevir-d7
Faldaprevir(BI 201335)
BI201335; BI 201335; BI-201335
(1R,2S)-N-[(Cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[8-bromo-7-methoxy-2-[2-[(2-methyl-1-oxopropyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-L-prolyl-1-amino-2-ethenyl-cyclopropanecarboxylic acid
Cyclopropanecarboxylic acid, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[8-bromo-7-methoxy-2-[2-[(2-methyl-1-oxopropyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-L-prolyl-1-amino-2-ethenyl-, (1R,2S)- | [Molecular Formula]
C40H49BrN6O9S | [MDL Number]
MFCD22572729 | [MOL File]
801283-95-4.mol | [Molecular Weight]
869.82 |
| Hazard Information | Back Directory | [Uses]
Faldaprevir (BI 201335) is a potent, orally active and selective noncovalent inhibitor of NS3/4A protease of HCV (hepatitis C virus) genotypes 1a and 1b, with Ki values of 2.6 and 2.0 nM, respectively. Faldaprevir inhibits HCV RNA replication, with EC50 values of 6.5 and 3.1 nM, respectively. Faldaprevir has potent antiviral activity against chronic HCV infection[1][2]. | [References]
[1] Llinàs-Brunet M, et al. Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335). J Med Chem. 2010 Sep 9;53(17):6466-76. DOI:10.1021/jm100690x
[2] Zeuzem S, et al. Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results. Antivir Ther. 2013;18(8):1015-9. DOI:10.3851/IMP2567 |
|
| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
|